Kymab is a clinical-stage biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available. Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. It has a broad pipeline of therapeutic antibody programmes in immune-oncology, auto-immunity, haematology, infectious disease and other areas.
Select investors Woodford Investment Management, Malin, Bill & Melinda Gates Foundation, Wellcome Trust, ORI Capital
Last update: May 13, 2018
Disclaimer: We can not guarantee that the information on this page is 100% correct. more